ArticleJournal of translational medicine2005
T cell avidity and tumor recognition: implications and therapeutic strategies.
Article in Journal of translational medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Tumor microenvironment assessment-based signatures for predicting response to immunotherapy in non-small cell lung cancer.iScience · 2024Article
- COVID-19 in patients with cancer: Risks and precautions.The American journal of emergency medicine · 2021Article
- Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors.Nanoscale · 2021Article
- Article
- Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment.Cellular & molecular immunology · 2020Review
- Identification of non-mutated neoantigens presented by TAP-deficient tumors.The Journal of experimental medicine · 2018Article
- A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.Human vaccines & immunotherapeutics · 2017Article
- Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.Oncoimmunology · 2016Article
- Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.International journal of oncology · 2013Article
- Article
- Mathematical modeling of oncogenesis control in mature T-cell populations.Frontiers in immunology · 2013Article
- Article
- Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3.The Journal of general virology · 2012Article
- Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.Self/nonself · 2011Article
- Tumour-associated antigens: considerations for their use in tumour immunotherapy.International journal of hematology · 2011Review
- Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.Cancer immunology, immunotherapy : CII · 2009Article
- Article
- Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.Cancer immunology, immunotherapy : CII · 2007Article
- Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.Cancer immunology, immunotherapy : CII · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the last two decades, great advances have been made studying the immune response to human tumors. The identification of protein antigens from cancer cells and better techniques for eliciting antigen specific T cell responses in vitro and in vivo have led to improved understanding of tumor recognition by T cells. Yet, much remains to be learned about the intricate details of T cell-tumor cell interactions. Though the strength of interaction between T cell and target is thought to be a key factor influencing the T cell response, investigations of T cell avidity, T cell receptor (TCR) affinity for peptide-MHC complex, and the recognition of peptide on antigen presenting targets or tumor cells reveal complex relationships. Coincident with these investigations, therapeutic strategies have been developed to enhance tumor recognition using antigens with altered peptide structures and T cells modified by the introduction of new antigen binding receptor molecules. The profound effects of these strategies on T cell-tumor interactions and the clinical implications of these effects are of interest to both scientists and clinicians. In recent years, the focus of much of our work has been the avidity and effector characteristics of tumor reactive T cells. Here we review concepts and current results in the field, and the implications of therapeutic strategies using altered antigens and altered effector T cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.